Abbott Laboratories (ABT) Receives ‘Analyst’ Rating

Abbott Laboratories (ABT) : 15 analysts are covering Abbott Laboratories (ABT) and their average rating on the stock is 1.6, which is read as a Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Abbott Laboratories (ABT) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Abbott Laboratories (ABT) : Average target price received by Abbott Laboratories (ABT) is $48.46 with an expected standard deviation of $1.44. The most aggressive target on the stock is $50, whereas the most downbeat target is $45. 11 financial analysts are currently covering the stock.


Also, Equity analysts at the Brokerage firm Jefferies maintains its rating on Abbott Laboratories (NYSE:ABT). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Jefferies raises the price target from $49 per share to $52 per share. The rating by the firm was issued on August 4, 2016.

Abbott Laboratories (NYSE:ABT): After opening at $40.79, the stock dipped to an intraday low of $40.65 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $41.255 and the buying power remained strong till the end. The stock closed at $41.12 for the day, a gain of 0.76% for the day session. The total traded volume was 6,100,131. The stocks close on the previous trading day was $40.81.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.